China-based Guangzhou Innogen Pharmaceutical Group Co., Ltd, a biopharma focused on metabolic diseases, announced the global launch of its efsubaglutide alfa, a next-generation ultra-long-acting glucagon-like peptide 1 (GLP-1) receptor agonist for the treatment of type 2 diabetes (T2D), in Changshu, Jiangsu province.
Drug Profile
Efsubaglutide alfa, with an average half-life of up to 204 hours in T2D patients, received marketing approval in China last month. The drug’s ultra-long-acting profile offers a significant advantage in patient treatment adherence.
Partnership
Innogen has partnered with Intellective Biologics (Suzhou) Co., Ltd. to advance the manufacturing and commercialization of efsubaglutide alfa. The collaboration aims to ensure the drug’s successful market entry and widespread availability.-Fineline Info & Tech
Leave a Reply